Can we risk transplantation across positive complement-dependent cytotoxicity crossmatches in pediatric patients?
- PMID: 29947127
- DOI: 10.1111/ajt.14986
Can we risk transplantation across positive complement-dependent cytotoxicity crossmatches in pediatric patients?
Keywords: clinical trial; editorial/personal viewpoint; heart transplantation/cardiology; immunosuppressant; immunosuppression/immune modulation; organ transplantation in general; panel reactive antibody (PRA); plasmapheresis/plasma exchange.
Comment on
-
Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study.Am J Transplant. 2018 Sep;18(9):2163-2174. doi: 10.1111/ajt.14691. Epub 2018 Mar 24. Am J Transplant. 2018. PMID: 29442424 Free PMC article.
-
Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation.Am J Transplant. 2018 Sep;18(9):2135-2147. doi: 10.1111/ajt.14695. Epub 2018 Mar 23. Am J Transplant. 2018. PMID: 29446208 Free PMC article.
-
Pediatric heart transplantation across a positive crossmatch: First year results from the CTOTC-04 multi-institutional study.Am J Transplant. 2018 Sep;18(9):2148-2162. doi: 10.1111/ajt.14876. Epub 2018 May 28. Am J Transplant. 2018. PMID: 29673058
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials